Tonix Pharmaceuticals closes it public offering

Tonix Pharmaceuticals Holding (TNXP -2.3%) slips after announcing the closing of its 2.6M share public offering of $4.25 per unit, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.

The company expects to use net proceeds from this offering to fund the clinical development of TNX-102 SL, for which a Phase 2b/3 clinical trial for the treatment of fibromyalgia is in process to begin in the Q313.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs